요 검체에서 분리된 Morganella morganii의 Metallo-ß-Lactamase VIM-2 유전자 Cassette를 포함하는 새로운 Integron

김택상,김종철,정석훈 대한비뇨의학회 2004 Investigative and Clinical Urology Vol.45 No.6

내 가슴속에서 사는 기정이

김택상 샘터사 1997 월간 샘터 Vol.28 No.3

진행성 요로상피암에서 Gemcitabine-Cisplatin 병합요법과 M-VAC 병합요법의 비교연구

김택상,류현열 고신대학교(의대) 고신대학교 의과대학 학술지 2004 고신대학교 의과대학 학술지 Vol.19 No.1

Background : To evaluate the response and toxicity of gemcitabine and cisplatin combination chemotherapy comparing to M-VAC chemotherapy in advanced urothelial cell carcinoma. Methods : We analyzed toxicity of forty nine patients with advanced urothelial cell carcinoma received gemcitabine and cisplatin combination chemotherapy at least 1 cycle, and fifty four patients with advanced urothelial cell carcinoma received M-VAC chemotherapy at least 1 cycle. We also analyzed response of twenty one patients received six cycle gemcitabine and cisplatin combination chemotherapy and thirty two patients received four cycle M-VAC chemotherapy. Results : In advanced urothelial cell carcinoma, gemcitabine and cisplatin combination chemotherapy shows almost same response comparing to M-VAC chemotherapy (61.5:56.25%). Furthermore, it has much less hematologic and systemic toxicity than M-VAC chemotherapy, which was marked reduced fatal leukocytopenia (8.2:48%), sepsis (0.4:6.4%), stomatitis (0:41.5%). In M-VAC chemotherapy, leukocytopenia and sepsis were predominent in the first and second cycle, but alopecia and mucositis increased with cycles. In gemcitabine and cisplatin combination chemotherapy, leukocytopenia and thrombocytopenia appeared in 2nd or 3rd cycle. After treatment with GM-CSF or transfusion, they were not predominant. Many patients who received M-VAC chemotherapy could not complete full four cycle because of severe toxicity. In gemcitabine and cisplatin combination chemotherapy, adverse effects appeared in 2nd or 3rd cycle. After correction, these adverse effects were reversible and tolerable. Conclusion : Gemcitabine and cisplatin combination chemotherapy showed almost same response and marked reduced toxicities comparing to M-VAC chemotherapy. We anticipate to improve of quality of life and replace of M-VAC chemotherapy.

전립선비대증 환자에서 TURP, ILC, TUNA 및 TEAP 시술의 효과와 안전성의 비교연구

김택상,최성,류현열,안정환,장진호,조문환 대한비뇨의학회 2006 Investigative and Clinical Urology Vol.47 No.1

열화시스템의 수리를 위한 베이지안 의사결정 모형의 개발

김택상,안선응 한국산업경영시스템학회 2005 한국산업경영시스템학회 학술대회 Vol.2005 No.추계

This paper is intended to develop a Bayesian decision model for the repair of deteriorating system. A non-homogeneous Poisson process with a power law failure intensity function is used to describe the behavior of the deteriorating repairable system. The decision on whether to have minimal repair or imperfect repair should be made on the occurrence of a failure. However, it is difficult to make a reasonable decision due to many uncertainties intrinsic in repair actions. In this paper, prior distributions are used in order to analyze the uncertainties embedded in the decision alternatives. Especially, a prior distribution for imperfect repair with probabilistic reduction in the failure intensity is proposed. In addition, mathematical expressions to calculate the expected prior loss of each repair alternative are proposed.

석사논문경진대회 : 열화시스템의 수리를 위한 베이지안 의사결정 모형의 개발

김택상,안선응 대한산업공학회 2005 대한산업공학회 추계학술대회논문집 Vol.2005 No.-

Pilot Study of the Clinical Significance of Serum and Urinary HER-2/neu Protein in Bladder Cancer Patients

김택상,류현열,황현용 대한비뇨의학회 2011 Investigative and Clinical Urology Vol.52 No.12

Purpose: HER-2/neu overexpression is documented in some bladder cancers. To our knowledge, there are no current studies evaluating urine HER-2/neu levels. Therefore, we examined the clinical significance of serum and urine HER-2/neu protein in bladder cancer. Materials and Methods: Urothelial bladder carcinoma patients (n=38, including 31 men and 7 women) and healthy controls (n=25, including 20 men and 5 women) were included in the study. Urine cytology and serum and urine HER-2/neu levels were measured before the transurethral resection of bladder tumor procedure. Prognostic factors including tumor stage, histologic grade, tumor size, multiplicity, and preoperative urine cytology and their association with urinary HER-2/neu were analyzed by simple and multiple regression analyses. Results: There was no significant difference in serum HER-2/neu between the two groups (p=0.489). The mean urinary HER-2/neu was 7,586.82 relative luminescence unit (RLU) in bladder cancer patients and 4,245.84 RLU in healthy controls. The mean RLU values of urinary HER-2/neu in the bladder cancer patient group were significantly higher than in healthy controls (p=0.012). An receiver operating characteristic curve was generated, and using the cutoff value of ≥4,800 RLU of urinary HER-2/neu, 71.1% sensitivity and 84.0% specificity were obtained. Among the clinical factors, only positive preoperative urine cytology samples were associated with urinary HER-2/neu levels by both simple and multiple regression analyses. Conclusions: Bladder cancer patients demonstrated significantly higher urinary HER-2/neu than did healthy controls. These findings suggest that urinary HER-2/neu may be valuable as a new urinary marker. The application of urinary HER-2/neu needs additional investigation.

Current Status of Laparoscopic Partial Nephrctomy

김택상 고신대학교(의대) 고신대학교 의과대학 학술지 2013 고신대학교 의과대학 학술지 Vol.28 No.2

Recently, nephron-sparing,minimally invasive surgery of small renal masses has become popular. The most typical surgery is laparoscopic partial nephrectomy (LPN). However, due to technical difficulties, the indications for LPN had been limited to small, exophytic, and peripheral tumors. This paper introduces current status of oncological outcomes and technical considerations.

임상적 국소전립선암 환자에서 시행한 일차적 남성호르몬차단요법 단독치료의 효과

김택상,강수환,류현열 대한비뇨의학회 2009 Investigative and Clinical Urology Vol.50 No.11

Purpose: The purpose of this study was to evaluate the characteristics of patients who received primary androgen deprivation therapy (PADT) for clinically localized prostate cancer and the clinical efficacy of this treatment. Materials and Methods: Between January 1998 and August 2007, patients who underwent PADT for clinically localized prostate adenocarcinoma were analyzed. The patients studied could not receive definitive therapy owing to old age or medical comorbidities. All patients’ Gleason score, pretreatment prostate-specific antigen (PSA) value, time to PSA progression, and D’Amico’s risk criteria were analyzed. Results: A total of 72 patients were analyzed. The patients’ mean age was 75.29 years (range, 57-92 years) and their median pretreatment PSA was 13.52 ng/ml (range, 1.27-74.82 ng/ml). The median follow-up duration was 39 months (range, 18-115 months). Thirteen patients (18.57%) had PSA progression after reaching a PSA nadir. The mean time to PSA progression was 14 months (range, 7-55 months). Among these 13 patients, 2 patients had low-risk prostate cancer and 11 patients had high-risk prostate cancer by D’Amico’s risk criteria. Three of the 13 patients are now receiving chemotherapy, 2 patients died from cancer progression, 3 patients died of a non-cancer cause, and 5 patients are now being conservatively managed. Of the total 72 patients, 70.83% of the patients are still receiving PADT. A total of 11 patients died; however, only 2 deaths were caused by prostate cancer. Conclusions: In patients with localized prostate cancer who could not receive definitive therapy for several reasons, the cancer-caused death rate was very low, even in patients with PSA progression. PADT is an effective therapeutic option in patients with localized prostate cancer. Purpose: The purpose of this study was to evaluate the characteristics of patients who received primary androgen deprivation therapy (PADT) for clinically localized prostate cancer and the clinical efficacy of this treatment. Materials and Methods: Between January 1998 and August 2007, patients who underwent PADT for clinically localized prostate adenocarcinoma were analyzed. The patients studied could not receive definitive therapy owing to old age or medical comorbidities. All patients’ Gleason score, pretreatment prostate-specific antigen (PSA) value, time to PSA progression, and D’Amico’s risk criteria were analyzed. Results: A total of 72 patients were analyzed. The patients’ mean age was 75.29 years (range, 57-92 years) and their median pretreatment PSA was 13.52 ng/ml (range, 1.27-74.82 ng/ml). The median follow-up duration was 39 months (range, 18-115 months). Thirteen patients (18.57%) had PSA progression after reaching a PSA nadir. The mean time to PSA progression was 14 months (range, 7-55 months). Among these 13 patients, 2 patients had low-risk prostate cancer and 11 patients had high-risk prostate cancer by D’Amico’s risk criteria. Three of the 13 patients are now receiving chemotherapy, 2 patients died from cancer progression, 3 patients died of a non-cancer cause, and 5 patients are now being conservatively managed. Of the total 72 patients, 70.83% of the patients are still receiving PADT. A total of 11 patients died; however, only 2 deaths were caused by prostate cancer. Conclusions: In patients with localized prostate cancer who could not receive definitive therapy for several reasons, the cancer-caused death rate was very low, even in patients with PSA progression. PADT is an effective therapeutic option in patients with localized prostate cancer.

진행성 요로상피암에서 Gemcitabine-Cisplatin 병합요법과 M-VAC 병합요법의 비교연구

김택상,류현열 고신대학교 의학부 2004 高神大學校 醫學部 論文集 Vol.19 No.1

Background: To evaluate the response and toxicity of gemcitabine and cisplatin combination chemotherapy comparing to M-VAC chemotherapy in advanced urothelial cell carcinoma. Methods : We analyzed toxicity of forty nine patients with advanced urotheial cell carcinoma received gemcitabine and cisplatin combination chemotherapy at least 1 cycle, and fifth four patients with advanced urothelial cell carcinoma received M-VAC chemotherapy at least 1 cycle. We also analyzed response of twenty one patients received six cycle gemcitabine and cisplatin combination chemotherapy and thirty two patients received four cycle M-VAC chemotherapy. Results : In advanced urothelial cell carcinoma., gemcitabine and cisplatin combination chemotherapy shows almost same response comparing to M-VAC chemotherapy (61.8:56.25%). Furthermore, it has much less hematologic and systemic toxicity than M-VAC chemotherapy, which was marked reduced fatal leukocytopentia (8.2:4.8%), sepsis (0.4:6.4%), stomatitis (0:41.5%). In M-VAC chemotherapy, leukocytopenia and sepsis were predominent in the first and second cycle, but alopecia and mucositis increased with cycles. In gemcitiabine and cisplatin combination chemotherapy, leukocytopenia and thrombocytopenia appeared in 2nd or 3rd cycle, After treatment with GM-CSF of transfusion, they were not predominent. Many patients who received M-VAC chemotherapy could not complete full four cycle because of severe toxicity. In gemcitabine and cisplatin combination chemotherapy, adverse effects appeared in 2nd or 3rd cycle. After correction, these adverse effects were reversible and tolerable. Conclusion :Gemcitabine and cisplatin combination chemotherapy showed almost same response and marked reduced toxicities comparing to M-VAC chemotherapy. We anticipate to improve of quality of life and replace of M-VAC chemotherapy.